Alembic Pharmaceuticals, a Vadodara based vertically integrated research and development pharmaceutical company,  has announced consolidated net profit growth of 40.4 per cent during the fourth quarter ended March 2014 to Rs. 61.29 crore from Rs. 43.65 crore int the corresponding period of last year. Its EBDITA also increased by 43.3 per cent to Rs. 94.06 crore from Rs. 65.65 crore. The company's consolidated net sales increased by 23 per cent to Rs. 463.33 crore from Rs. 376.58 crore.

The company's research and development expenditure increased by 37.6 per cent to Rs. 31.20 crore from Rs. 22.67 crore and employees cost went up by 32.3 per cent to Rs. 67.15 crore from Rs. 50.77 crore in the similar quarter of last year. The board of directors has recommended equity dividend of 150 per cent i.e. Rs. 3 per share of Rs. 2 each.   

The company's consolidated net sales for the full year ended March 2014 increased by 22.7 per cent to Rs. 1,861 crore from Rs. 1,517 crore in the previous year. Its net profit touched to Rs. 236 crore as against Rs. 165 crore, a strong growth of 43 per cent. Its EBDITA also went up by 41 per cent to Rs. 361 crore from Rs. 256 crore.

Its sales of India branded formulations improved by 14 per cent to Rs. 851 crore from Rs. 748 crore. Its specialty segment grew by 17 per cent, but acute segments sales declined by 3 per cent. Its sales of international generic formulation went up sharply by 99 per cent to Rs. 468 crore from Rs. 236 crore in the previous year.

The company filed total four ANDAs and 6 DMFs during 2013-14 and its cumulative ANDA filings reached at 61. It received approval for 8 ANDAs during the year under review and its total reached at 32 ANDAs (including 4 tentative approvals). The cumulative DMF filings reached at 66.